Identification & Characterization of Ovarian Cancer & Endometrial Cancer

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to:

1. Identification and characterization of ovarian carcinoma well-known biomarkers, carcinoma antigen 125 (CA125) and Human epididymis protein 4 (HE4) and other potential biomarkers in vaginal fluids obtained from ovarian cancer patients.

2. Quantification and calibration of identified biomarkers in vaginal discharge collected from ovarian cancer patients in comparisons to samples collected from healthy volunteers.

3. Comparison analysis of biomarkers levels in vaginal fluids vs. serum.

4. Quantification and calibration of identified biomarkers in vaginal discharge collected from ovarian cancer patients diagnosed in various stages.

Clinical Trial Description

Initially, twenty vaginal fluid samples will be collected from ovarian cancer patients diagnosed with epithelial ovarian carcinoma at advanced diagnosis stage.

The samples will be used to identify specific biomarkers as describe above. Biomarkers levels will be calibrated compared to their vaginal fluids obtained from healthy volunteers. In addition, five milliliters of venous blood will be collected from same patients in order to compare biomarkers vaginal fluids levels vs serum levels. All patients will sign a consent form which approve that their vaginal fluid samples will be utilized for research according to Helsinki approval.

At the second phase of the research, additional twenty vaginal fluids samples will be collected from patients diagnosed at different stages (five samples from each of main stages 1-4). Sample will be used to calibrate biomarkers levels in various diagnosis stages and will be compare to serum levels from venous blood samples which will be also collected from the same patients.

All patients will sign a consent form following explanation on research goals. Patient will be notified that participation in this research will have no implication on medical treatment plan.

Note that in all research phases there will be no returning of samples to the patients, all identification and characterization procedures will be performed in vitro for research properties only.

Methodology

- Collecting vaginal fluids samples from ovarian cancer patients. Vaginal fluids (at least 400µl, the investigators wish to have 1000 µl) will be collected during surgery or during routine physical examination using specific applicator/cotton swab/syringe. Samples will be shipped to GinaLife Diagnostics laboratory for analysis. In addition, on the day of vaginal fluids collection 5 ml of peripheral blood samples will be drawn from each volunteer.

- Analyzing specific biomarkers in samples. Vaginal fluids will be analyzed using commercial enzyme-linked immunosorbent assay (ELISA) kits to determine the presence and the concentrations of various proteins. In addition, western blot analysis will be used in order to confirm ELISA assay results. Specific nucleic acid will be determine using common molecular methods such as Reverse transcription polymerase chain reaction (RT-PCR) etc.

- Data analysis ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02704650
Study type	Interventional
Source	Shaare Zedek Medical Center
Contact
Status	Withdrawn
Phase	N/A
Start date	May 2016
Completion date	December 2017

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT02432378` - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines	Phase 1/Phase 2
Terminated	`NCT02669914` - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors	Phase 2
Recruiting	`NCT05059782` - Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer	N/A
Terminated	`NCT03162562` - The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer	Phase 1
Recruiting	`NCT04438564` - Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients	N/A
Recruiting	`NCT05252390` - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT05246462` - The Effect of Logotherapy on Mental Health in Gynecological Cancer Patients	N/A
Completed	`NCT01595204` - Validation of a Laparoscopic Score to Predict the Chance of Optimal Cytoreduction in Advanced Ovarian Cancer Patients	N/A
Not yet recruiting	`NCT06268665` - Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy	Phase 2
Terminated	`NCT01535157` - Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer	Phase 1/Phase 2
Completed	`NCT02582931` - MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer	Phase 1
Recruiting	`NCT03133286` - Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Identification and Characterization of Ovarian Cancer and Endometrial Cancer Specific Biomarkers in Vaginal Fluids

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms